Skip to content

Clinical Efficacy Observation of thumbtack needling Combined with "Qimai Shihu Yin" Treatment for Dry Eyes

Clinical Efficacy Observation of thumbtack needling Combined with "Qimai Shihu Yin" Treatment for Dry Eyes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000444
Enrollment
Unknown
Registered
2025-03-02
Start date
2025-03-05
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

The combination of thumb-tack needle and Qimibai Shihu Drink group:The combination ofartificial tears,thumb-tack needle and Qimibai Shihu Drink
The artificial tears group:Polyvinyl alcohol eye drops 1 drop 3 times a day
The Qimibai Shihu Drink group:Artificial tears treatment + Chinese medicine tea drink-Qimibai Shihu Drink (Qimibai Shihu Drink: lycium, ophiopogon japonicus, dendrobium, huangjing, radix pseudostellar
The thumb-tack needle group:Artificial tears treatment + snap-needle treatment at specific acupoints. The selected points were Sizhukong, Sun, and Sanyinjiao, and the treatment was carried out once a

Sponsors

Nanjing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for dry eye; 2. 18 years old = age = 60 years old; 3. No adverse reaction to needling and skin dressing; 4. Informed consent and volunteer to be tested. The process of obtaining informed consent should be in accordance with GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Those who are being treated for other eye diseases; 2. Those who are using other means of dry eye treatment; 3. With eye diseases such as keratoconjunctival lesions and tear duct blockage; 4. History of eye medication within three months; 5. History of eye surgery and trauma within three months; 6. History of wearing corneal contact lenses within three months; 7. Pregnant and breastfeeding women; 8. Patients with major systemic diseases such as heart brain kidney and so on; 9. Mental illness and others who are unable to cooperate with the treatment or give full informed consent; 10. According to the judgment of the researcher the possibility of enrollment is reduced or complicated by other medical conditions such as frequent changes in the work environment and other conditions that may lead to loss of visits; 11. Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
FL;S?T;BUT;

Secondary

MeasureTime frame
Whole body symptom score;Eye symptom score;Meibomian gland function;Questionnaire about Eye Symptoms and Daily Life;TMH;

Countries

China

Contacts

Public ContactYing Yang

Nanjing University of Chinese Medicine

1072294379@qq.com+86 181 9455 9298

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026